Key Takeaway
Most adults lose 15-22.5% of their body weight on Zepbound over 72 weeks. Learn about SURMOUNT trial results, dose-dependent outcomes, timelines, and what factors influence your weight loss.
Most adults lose between 15% and 22.5% of their body weight on Zepbound (tirzepatide) over 72 weeks, depending on the dose. At the highest dose of 15 mg, participants in the SURMOUNT-1 trial[1] lost an average of 22.5% of their body weight, which is the largest average weight loss recorded for any single anti-obesity medication. For a closer look at real patient transformations, see our Zepbound before and after results page.
Clinical Trial Results for Zepbound
Zepbound was approved by the FDA in November 2023 for chronic weight management. It contains tirzepatide, a dual GIP/GLP-1 receptor agonist that activates two incretin pathways simultaneously. This dual mechanism is believed to drive the greater weight loss observed compared to single-agonist GLP-1 medications like semaglutide.
SURMOUNT-1: The important Trial
SURMOUNT-1 enrolled 2,539 adults[1] with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition, without diabetes. All participants received lifestyle counseling. Results at 72 weeks:
- Zepbound 5 mg: 15.0% average body weight loss
- Zepbound 10 mg: 19.5% average body weight loss
- Zepbound 15 mg: 22.5% average body weight loss
- Placebo: 3.1% average body weight loss
At the 15 mg dose:
- 96% of participants lost at least 5% of body weight
- 84% lost at least 10%
- 63% lost at least 20%
- 36% lost 25% or more
SURMOUNT-2[2]: Results in People With Diabetes
SURMOUNT-2 studied Zepbound in 938 adults with both obesity and type 2 diabetes. At 72 weeks:
- Zepbound 10 mg: 12.8% average weight loss[4]
- Zepbound 15 mg: 14.7% average weight loss
Weight loss is consistently lower in patients with diabetes across all GLP-1 class medications, but these results still represent clinically meaningful outcomes.
SURMOUNT-4[3]: What Happens After Stopping
SURMOUNT-4 gave all participants Zepbound for 36 weeks, then randomized them to continue or switch to placebo. Those who continued Zepbound lost an additional 5.5% of body weight over the next year. Those switched to placebo regained approximately 14 percentage points, ending up having kept only about half their initial weight loss. This trial clearly demonstrated the need for ongoing treatment.
What That Means in Real Numbers
At the 15 mg dose (22.5% average loss):
- Starting at 200 pounds: approximately 45 pounds lost
- Starting at 250 pounds: approximately 56 pounds lost
- Starting at 300 pounds: approximately 68 pounds lost
At the 10 mg dose (19.5% average loss):
- Starting at 200 pounds: approximately 39 pounds lost
- Starting at 250 pounds: approximately 49 pounds lost
- Starting at 300 pounds: approximately 59 pounds lost
Weight Loss Timeline
Zepbound follows a gradual dose escalation over at least 20 weeks:
- Weeks 1-4 (2.5 mg): Starting dose for tolerability. Expect 2-5 pounds of weight loss.
- Weeks 5-8 (5 mg): First therapeutic dose. Weight loss becomes more noticeable.
- Weeks 9-20 (escalation through 7.5, 10, 12.5, 15 mg): Rapid weight loss phase. Many patients see 8-12% body weight loss by week 20.
- Weeks 20-72 (maintenance dose): Continued weight loss at a gradually decreasing rate. Most of the total result is achieved by months 12-15.
What Influences Your Personal Outcome
- Dose level: There's a clear dose-response relationship. The 15 mg dose produces about 50% more weight loss than 5 mg. Your physician will titrate based on your tolerance and response.
- Diabetes: Having type 2 diabetes reduces expected weight loss by approximately 6-8 percentage points at the same dose.
- Diet and exercise: All trial participants received structured lifestyle counseling. Real-world results depend heavily on dietary adherence and activity level.
- Consistency: Missing doses disrupts the medication's sustained effect on appetite and metabolism.
- Biological factors: Individual genetics, gut microbiome composition, and baseline hormone levels all contribute to how strongly any person responds to tirzepatide.
What to Consider
Zepbound's clinical trial results are impressive, but they represent averages. Some patients exceed 30% weight loss while others may lose less than 10%. Your physician can help you set appropriate expectations based on your health profile, starting weight, and other factors.
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
The dose titration period takes at least 20 weeks, so patience during the early months is important. Gastrointestinal side effects such as nausea are most common during dose increases and typically improve once a stable dose is reached.
Zepbound is designed for long-term use. SURMOUNT-4 data clearly showed that stopping the medication leads to substantial weight regain. A sustainable, long-term treatment plan should be part of your initial conversation with your physician.
Frequently Asked Questions
Do I need a prescription for How Much Weight Will I?
Yes, GLP-1 receptor agonists require a prescription from a licensed healthcare provider. You can obtain a prescription through an in-person visit or a telehealth consultation with a qualified provider.
What are the most common side effects of How Much Weight Will I?
The most frequently reported side effects include nausea (especially during dose escalation), decreased appetite, and mild gastrointestinal discomfort. These typically improve as your body adjusts to the medication over 2-4 weeks.
How long does it take for How Much Weight Will I to show results?
Most patients begin noticing effects within 4-8 weeks of starting treatment. Full results for weight management typically appear over 12-16 weeks with consistent use and lifestyle modifications.
Medical References
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. [PubMed | ClinicalTrials.gov | DOI]
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626. [PubMed | ClinicalTrials.gov | DOI]
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48. [PubMed | ClinicalTrials.gov | DOI]
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. [PubMed | ClinicalTrials.gov | DOI]
Start Your Zepbound process with FormBlends
FormBlends provides physician-supervised tirzepatide therapy with personalized dosing, regular check-ins, and thorough medical support. Every treatment plan starts with a thorough evaluation to ensure Zepbound is safe and appropriate for you. Start your consultation today.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →